Large Scale Sequencing Projects & Data Sharing Flashcards
List some flagship large scale genome sequencing projects
- UK: 100,000 genomes project
- USA: 1 million genomes (All of Us programme)
- Saudi Arabia: 100,000
- EU: Personalising Medicine programme
- Scotland: 3000 genome project
What are the aims of the 100,000 genome project in the UK?
- Kickstart UK genomics industry
- Identify new genes for diagnosis, drug target, precision medicine etc (Research)
- Develop ethical and transparent method of testing and consent. By developing standardised, crowdsourced panels, held in PanelApp, patients tested across the country and guaranteed the same analysis. Consent for primary and secondary findings taken separately.
- Introduce genomic testing into the NHS.
What are the challenges faced by the 100,000 genome project in the UK?
- Recruitment – expected to have had common causes of their phenotype excluded. Needs good balance between trio vs solo
- Data generation - limitations to selected assay
- Data processing/analysis - QC/BIs
- Data interpretation throughput and variant interpretation, VUS’s and incidental findings
- Bottlenecks in process e.g. clinical data entry, processing, data analysis/interpretation
- Data sharing
Why is sharing specifically of genomic data becoming so important?
- Genomic data is a key component for the diagnosis and management of patients with rare disease and cancer.
- The sharing of genomic data from patients and the general population enables experts to;
- Determine the genetic basis of undiagnosed diseases
- Refine interpretation and diagnoses of rare diseases and cancer
- Improve patients’ care via personalised medicine
What key considerations should be addressed when sharing genomic data?
- Who is data being shared with? How will the data be used?
- Where is the data stored? Cloud vs local installation/virtual desktop
- Privacy
- Patient Confidentiality
- Data sharing and patient consent
- Data security and information governance, Caldicott.
- National or international sharing?
What pressures can make laboratories reluctant to share data?
- Currently no guidelines relating to best practice of sharing of data - labs conserned of doing something wrong.
- Sharing data outside of national borders can be subject to strict regulation - labs do not want to be liable for breaking laws.
How can large scale sequencing projects facilitate the sharing of genomic data?
- A large centralised project facilitates gathering variant data in one place vs locally stored in individual lab silos.
- The resources backing large scale programmes enable dedicated teams to tackle problems liek data sharing which smaller groups may not have.
Which organisations and programmes are trying to address the problems of data sharing?
- GEL plan to implement a central national repository for the storage and sharing of data generated in the 100KGP
- Global Alliance for Genomics and Health
- Matchmaker exchange
- BRCA challenge
All of these groups aim to facilitate data sharing but there remain questions regarding who controls and owns the data?
Who are the key groups that may benefit from the sharing of genomic data?
- Healthcare Professionals
- Patients and families
- General populations
- Academic Research groups
What are the key benefits to Healthcare Professionals?
- Help establish genotype-phenotype correlations to better identify clinically significant variants
- Enable improved and faster diagnosis thereby saving time and resources (i.e. efficiency savings)
- Inform therapeutic decisions and enhance preventive care
- Improve clinical outcomes and aid clinical decision-making
- Thus, global sharing achieves the greatest clinical utility
What are the challenges faced by Healthcare Professionals for sharing data?
- Uncertainty about the legality of data sharing
- Logistical - Lack of suitable and sustainable infrastructure for sharing data.
- Competition within the health system = disincentives to share data
- Lack of data sharing ‘standards’ or ‘guidelines’ - What data to share? Standard data ‘formats’ which are cross-compatible are required.
- Training professionals to effectively communicate the complexity of genomic testing to their patients
What are the key benefits to Patients and families?
- Easier and faster diagnosis (especially of rare disease) via patient ‘matchmaking’
- Elucidation of rare disease genes and discovery of new therapies leading to improved and tailored treatment (‘personalised medicine’) – reducing adverse effects
- Predictive testing for other family members
What are the challenges faced by Patients and families for sharing data?
- Implications of incidental findings, carrier status, adult onset disorders. Impact on wider family etc.
- Some data could be potentially identifiable information – especially WGS
- Patient consent – boundaries not clear for use of genomic data ?generic consent
- Risk of information being misused – requires safeguarding to assure security of data and data protection
What are the key benefits to the general population?
- Identification of population specific benign variation in order to avoid clinical misinterpretation which can follow when whole populations are underrepresented in databases
- Enabling ancestry matched controls leading to better interpretation of disease causing variation
- Will facilitate the integration of genomics into mainstream medicine ‘for-all’
What are the challenges faced by the general population for sharing data?
- Can raise difficult discussion around ‘race’ and ethnicity
- Stigmatisation through linking conditions to a particular population – could this lead to discrimination?